SCHEMBL516051

SCHEMBL516051

O=C(O)CN(C(=O)C=Cc1ccccc1)c1ccc(O)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPM8 Q7Z2W7 5/20 0.58
▸ CYP3A4 P08684 2/20 0.50
▸ HSPD1 P10809 2/20 0.50
▸ HSPE1 P61604 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ MAOB P27338 2/20 0.50
▸ MAPT P10636 2/20 0.50
▸ F3 P13726 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ ALDH2 P05091 1/20 0.50
▸ CYP19A1 P11511 1/20 0.50
▸ MAOA P21397 1/20 0.50
▸ CYP1B1 Q16678 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ NPC1 O15118 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ ALDH1A1 P00352 2/20 0.47
▸ MMP1 P03956 3/20 0.47
▸ MMP2 P08253 3/20 0.47
▸ MMP9 P14780 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL516050 1.00 TRPM8 (0.58) TRPM8CYP3A4HSPD1HSPE1KMT2A
SCHEMBL10220933 0.91 TRPM8 (0.69) TRPM8MAPTF3TDP1NPC1
SCHEMBL515634 0.87 TRPM8 (0.57) TRPM8KMT2AMAPTF3MEN1
SCHEMBL515635 0.87 TRPM8 (0.57) TRPM8KMT2AMAPTF3MEN1
SCHEMBL12060510 0.85 NPC1 (0.60) TRPM8CYP3A4HSPD1HSPE1KMT2A
SCHEMBL10220934 0.75 TRPM8 (0.61) TRPM8TDP1NPC1L3MBTL1ALDH1A1
SCHEMBL28050166 0.74 NPC1 (0.57) TRPM8KMT2AMAOBMAPTF3
SCHEMBL8721921 0.74 TRPM8 (1.00) TRPM8NPC1L3MBTL1ALDH1A1RAB9A
SCHEMBL8721927 0.74 TRPM8 (1.00) TRPM8NPC1L3MBTL1ALDH1A1RAB9A
SCHEMBL179788 0.73 CA2 (0.43) ALDH1A1CA12CA4CA6CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2046739-B1 SUBSTITUTED ANILINE DERIVATIVES UCB BIOPHARMA SPRL (BE) 2015-08-26 — — EP disclosed
US-8624022-B2 Substituted aniline derivatives UCB PHARMA, S.A. (BE) 2014-01-07 — — US disclosed
US-20120029188-A1 Substituted Aniline Derivatives UCB PHARMA S.A. (BE) 2012-02-02 — — US disclosed
US-8071582-B2 Substituted aniline derivatives UCB PHARMA S.A. (BE) 2011-12-06 — — US disclosed
US-20110014271-A1 Substituted Aniline Derivatives UCB PHARMA S.A. (BE) 2011-01-20 — — US disclosed
US-7678785-B2 Substituted aniline derivatives UCB PHARMA S.A. (BE) 2010-03-16 — — US disclosed
EP-2046739-A1 SUBSTITUTED ANILINE DERIVATIVES UCB Pharma S.A. (BE) 2009-04-15 — — EP disclosed
US-20080045497-A1 SUBSTITUTED ANILINE DERIVATIVES UCB PHARMA S.A. (BE) 2008-02-21 — — US disclosed
WO-2008012524-A1 SUBSTITUTED ANILINE DERIVATIVES UCB PHARMA S.A. (BE) 2008-01-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120029188-A1 Substituted Aniline Derivatives NAT1, DPM1, IL4I1 TRPM8 4470/4885CYP3A4 41/4885HSPD1 952/4885
US-20080045497-A1 SUBSTITUTED ANILINE DERIVATIVES DPM1, ERG28, IL4I1 TRPM8 4349/4885CYP3A4 45/4885HSPD1 877/4885
US-20110014271-A1 Substituted Aniline Derivatives NAT1, DPM1, IL4I1 TRPM8 4470/4885CYP3A4 41/4885HSPD1 952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback